Carfilzomib, Pomalidomide, and Dexamethasone ± Daratumumab for Relapsed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 1/2 study of carfilzomib, pomalidomide, dexamethasone with and without daratumumab in relapsed multiple myeloma
Blood Adv 2023 Feb 10;[EPub Ahead of Print], BA Derman, JA Zonder, D Reece, CE Cole, JG Berdeja, AT Stefka, A Major, A Kin, KA Griffith, J Jasielec, AJ JakubowiakFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.